ArticleFrontiers in immunology2025
Skeletal muscle index combined with IgM predicts prognosis in gastric cancer patients who underwent surgery.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a prognostic model for major postoperative complications in gastric cancer patients undergoing laparoscopic gastrectomy.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to investigate the combination of skeletal muscle index (SMI) and immunoglobulin M (IgM) to form the SMI-IgM score to predict the prognosis of patients who underwent surgery for gastric cancer. Patients and methods: In this study, 190 patients operated for gastric cancer from July 2016 to December 2017 were collected. According to the optimal critical values of skeletal muscle index and immunoglobulin M, all patients were divided into three groups. We used Kaplan-Meier survival curves and log-rank test to assess the differences in progression-free survival time (PFS) and overall survival time (OS) between the 3 groups of patients. Independent predictors were identified using Cox regression, and nomogram plots were produced to predict confounded 1-, 3-, and 5-year survival rates based on independent predictors. Results: There were 68 patients (35.8%) in the SMI-IgM 1 group, 85 patients (44.7%) in the SMI-IgM 2 group, and 37 patients (19.5%) in the SMI-IgM 3 group. Patients in the SMI-IgM 1 group had worse PFS (HR = 0.345, 95% CI: 0.226-0.525, Conclusion: The SMI-IgM score could well respond to the nutritional and immune status of the body, and could be used as a new predictor for patients undergoing surgery for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.